Dogecoin Cash, Inc.: Form 10-Q for the period ended Jun 30, 2026

Certain statements in this Report constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Factors that might cause such a difference include, among others, uncertainties relating to general economic and business conditions; industry trends; changes in demand for our products and services; uncertainties relating to customer plans and commitments and the timing of orders received from customers; announcements or changes in our pricing policies or that of our competitors; unanticipated delays in the development, market acceptance or installation of our products and services; changes in government regulations; availability of management and other key personnel; availability, terms, and deployment of capital; relationships with third-party equipment suppliers; and worldwide political stability and economic growth. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made.

Results of Operations

Three Months Ended June 30, 2026 compared with the Three Months Ended June 30, 2025

Revenue for the three months ended June 30, 2026, decreased 13% compared to the three months ended June 30, 2025. Cost of revenues as a percentage of sales decreased 13% between the periods. The 13% revenue decrease was the result of sustained competitive pressure in the cannabis tele-medicine industry, where intensifying market competition has compressed demand growth through the second quarter of 2026.

Total operating expenses decreased 29% to $217,515 for the three months ended June 30, 2026, compared to $304,892 in Q2 2025. The decrease was driven by a 42% decrease in general and administrative expenses, a 11% decrease in wages and salaries and a 6% decrease in professional fees.

Six Months Ended June 30, 2026 compared with the Six Months Ended June 30, 2025

6

Revenue for the six months ended June 30, 2026, decreased 5% compared to the six months ended June 30, 2025. Cost of revenues as a percentage of sales decreased 7% between the periods. The decrease in revenues is primarily a result of the significant increase in competition for market share in the cannabis tele-medicine industry. This decrease in the demand for our service continued during the second quarter of 2026.

Total operating expenses decreased in June 30, 2026 compared with 2025 which trended down as did revenue in the current period. Increases in professional fees were offset by decreases in wages and salaries and general and administrative expenses. PrestoDoctor management salaries also decreased during the six months ended June 30, 2026.

4. Liquidity and Capital Resources

Cash used in operating activities was $22,132 in the six months ended June 30, 2026. We ended the second quarter of 2026 with $10,971 in cash on hand.

The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. We incurred net losses of $338,176 and $7,402,698, respectively, for the six months ended June 30, 2026 and 2025 and had an accumulated deficit of $84,714,880 as of June 30, 2026. The Company may seek to raise money for working capital purposes through a public offering of its equity capital or through a private placement of equity capital or convertible debt. It will be important for the Company to be successful in its efforts to raise capital in this manner if it is going to be able to further its business plan in an aggressive manner. Raising capital in this manner will cause dilution to current shareholders.

The amount of cash on hand the Company has does not provide sufficient liquidity to meet the immediate needs of our current operations.

Off Balance Sheet Arrangements

None

Disclosure Controls and Procedures

Conclusions of Management Regarding Effectiveness of Disclosure Controls and Procedures

At the end of the period covered by this Quarterly Report on Form 10-Q, an evaluation was carried out under the supervision and with the participation of the Company’s management, including the Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), of the effectiveness of the design and operations of the Company’s disclosure controls and procedures (as defined in Rule 13a – 15(e) and Rule 15d – 15(e) under the Exchange Act). Based on that evaluation, the CEO and the CFO have concluded that as of the end of the period covered by this report, the Company’s disclosure controls and procedures were not effective as it was determined that there were material weaknesses affecting our disclosure controls and procedures.

Management of the Company believes that these material weaknesses are due to the small size of the company’s accounting staff. The small size of the Company’s accounting staff may prevent adequate controls in the future, such as segregation of duties, due to the cost/benefit of remediation. To mitigate the current limited resources and limited employees, we rely heavily on direct management oversight of transactions, along with the use of external legal and accounting professionals. As the Company grows, management expects to increase the number of employees, which will enable us to implement adequate segregation of duties within the internal control framework.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting during the quarter ended June 30, 2026, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.